|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, newer clinical trials are currently ongoing to investigate whether SGLT2 inhibitors exhibit beneficial effects for HF, both in the presence and absence of T2D.
|
29801492 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent trials, sodium-glucose co-transporter-2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have both shown a significant reduction in HF hospitalization in patients with established CV disease or at risk of CV disease.
|
29520964 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pooled results show that SGLT2 inhibitors, when compared to placebo, significantly reduce all-cause mortality (OR 0.79, 95% CI 0.70-0.89; P < 0.001), major adverse cardiac events (OR 0.8, 95% CI 0.76-0.92; P < 0.001), non-fatal myocardial infarction (OR 0.85, 95% CI 0.73-0.98; P = 0.03) and heart failure/hospitalisation for heart failure (OR 0.67, 95% CI 0.59-0.76; P < 0.001) in patients with type 2 diabetes mellitus.
|
29372664 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
These effects may contribute to the protective effects of SGLT2 inhibitors on blood pressure and heart failure observed in diabetic patients with chronic kidney diseases.
|
29361669 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the EMPA-REG OUTCOME trial, SGLT2 inhibition with empagliflozin reduced the primary outcome of major adverse cardiovascular events (MACE), while also reducing mortality, hospitalization for heart failure, and progression of diabetic kidney disease.
|
29735306 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, large placebo-controlled outcome trials have shown that sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduce the risk of CV disease (including CV death and hospitalization for heart failure) in people with type 2 diabetes who are at high risk of atherosclerotic disease, and these effects were largely independent of improvements in hyperglycaemia, BP and body weight.
|
30524708 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes.
|
31584231 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are drugs for diabetes and might prevent heart failure.
|
31105148 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert opinion: DECLARE-TIMI 58 is the longest (4.2 years of follow up), largest (>17,000 participants) and most inclusive (only 41% of individuals with established atherosclerotic cardiovascular disease) CVOT raising the debate towards SGLT2 inhibitor therapy in primary prevention and the potential use of these drugs also in patients with HF without T2DM and other subpopulations.
|
30920851 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While little is yet known about SGLT subtype 1, SGLT2 inhibitors have demonstrated to significantly reduce cardiovascular mortality and heart failure hospitalizations.
|
31277431 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D).
|
31440988 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
While dipeptidyl peptidase-4 (DPP-4) inhibitors exhibited increased heart failure hospitalization in the SAVOR-TIMI 53 trial evaluating saxagliptin and in the secondary analysis of the EXAMINE trial for alogliptin, the effects of glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose co-transporter-2 (SGLT2) inhibitors on CV outcomes in diabetes have largely been positive.
|
30767126 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SGLT-2 inhibitors have opened a new perspective for clinicians treating patients with T2D and established CV disease in light of their 'pleiotropic' effects, specifically on heart failure, while GLP-1RAs seem to present more favourable effects on atherosclerotic events.
|
30888088 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, the DECLARE-TIMI 58 study (of dapagliflozin) clearly indicates strong protection for heart failure in those with CVD, and probably in those with no prior CVD.
|
30607467 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, novel drugs that have received interest in HF include angiotensin receptor blocker-neprilysin inhibitor (ARNi) and sodium glucose cotransporter 2 (SGLT-2) inhibitors, whose favorable cardiovascular profile has been at least partly attributed to their effects on metabolism.
|
30149104 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the available evidence, we conclude that SGLT-2 inhibitors represent an evidence-based therapeutic option for the primary prevention of heart failure hospitalization and secondary prevention of CVD in patients with T2DM, and should be considered early on in the treatment algorithm for patients with multiple risk factors, or those with established CVD.
|
31264765 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
At the present time, SGLT2 inhibitors are indicated for the treatment of type 2 diabetes; however, the results of ongoing trials in participants with heart failure but without diabetes are eagerly awaited.
|
31400090 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to determine whether empagliflozin (EMPA), an SGLT2 inhibitor, has a protective role in HF without diabetes.
|
31456369 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, there is growing evidence to illustrate the overall safety profile of this class of agents and support the benefit-risk profile of SGLT2 inhibitors as a preferred option following metformin monotherapy failure, with respect to both kidney disease progression and heart failure outcomes.
|
31410711 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent cardiovascular outcomes trials (CVOTs) have also shown that relative risk reductions in cardiovascular outcomes were observed with SGLT2 inhibition both in patients with current and prior heart failure.
|
31741439 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SGLT2 inhibitor class represents an important new therapeutic approach for the prevention of heart failure in at-risk patients with type 2 diabetes mellitus, and is actively being studied for use in treating patients with heart failure (with or without type 2 diabetes mellitus).
|
31741436 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current review article summarises these aspects and discusses possible mechanisms with SGLT2 inhibitors in protecting heart failure and renal dysfunction in diabetic patients.
|
31456521 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
For major cardiovascular events (MACE), there is no class effect for SGLT-2 inhibitors, as the 7% reduction of MACE risk observed with dapagliflozin in the DECLARE trial was not significant; on the other hand, a class effect is evident for both heart failure and diabetic kidney disease, as in all four trials so far completed (EMPAREG-OUTCOME, CANVAS, DECLARE, CREDENCE) the risk of hospitalization for heart failure and progression of diabetic kidney disease was significantly reduced by all SGLT-2 inhibitors.
|
31337395 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with GLP-1RAs and placebo, SGLT2 inhibitors led to a larger reduction in hospital admission for heart failure risk.
|
30653708 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
|
31474116 |
2019 |